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A gene expression signature of emphysema-
related lung destruction and its reversal by the
tripeptide GHK
Joshua D Campbell1,2, John E McDonough3, Julie E Zeskind1,2, Tillie L Hackett3, Dmitri V Pechkovsky3,
Corry-Anke Brandsma4, Masaru Suzuki3, John V Gosselink3, Gang Liu1, Yuriy O Alekseyev5, Ji Xiao1, Xiaohui Zhang1,
Shizu Hayashi3, Joel D Cooper6, Wim Timens4, Dirkje S Postma7, Darryl A Knight3, Marc E Lenburg1,2*,
James C Hogg3† and Avrum Spira1,2*
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease consisting of emphysema,
small airway obstruction, and/or chronic bronchitis that results in significant loss of lung function over time.
Methods: In order to gain insights into the molecular pathways underlying progression of emphysema and
explore computational strategies for identifying COPD therapeutics, we profiled gene expression in lung tissue
samples obtained from regions within the same lung with varying amounts of emphysematous destruction from
smokers with COPD (8 regions × 8 lungs = 64 samples). Regional emphysema severity was quantified in each
tissue sample using the mean linear intercept (Lm) between alveolar walls from micro-CT scans.
Results: We identified 127 genes whose expression levels were significantly associated with regional emphysema
severity while controlling for gene expression differences between individuals. Genes increasing in expression with
increasing emphysematous destruction included those involved in inflammation, such as the B-cell receptor
signaling pathway, while genes decreasing in expression were enriched in tissue repair processes, including the
transforming growth factor beta (TGFb) pathway, actin organization, and integrin signaling. We found concordant
differential expression of these emphysema severity-associated genes in four cross-sectional studies of COPD. Using
the Connectivity Map, we identified GHK as a compound that can reverse the gene-expression signature associated
with emphysematous destruction and induce expression patterns consistent with TGFb pathway activation.
Treatment of human fibroblasts with GHK recapitulated TGFb-induced gene-expression patterns, led to the
organization of the actin cytoskeleton, and elevated the expression of integrin b1. Furthermore, addition of GHK or
TGFb restored collagen I contraction and remodeling by fibroblasts derived from COPD lungs compared to
fibroblasts from former smokers without COPD.
Conclusions: These results demonstrate that gene-expression changes associated with regional emphysema
severity within an individual’s lung can provide insights into emphysema pathogenesis and identify novel
therapeutic opportunities for this deadly disease. They also suggest the need for additional studies to examine the
mechanisms by which TGFb and GHK each reverse the gene-expression signature of emphysematous destruction
and the effects of this reversal on disease progression.
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Background
Chronic obstructive pulmonary disease (COPD) is a sig-
nificant public health problem worldwide and the third
leading cause of death in the United States [1]. It is char-
acterized by irreversible airflow limitation due to obstruc-
tion in the small conducting airways and emphysematous
destruction of the gas exchanging tissue of the lung.
Tobacco smoke is a significant risk factor for COPD and
at least 25% of smokers develop this disease [2]. Current
theories concerning disease pathogenesis include an
imbalance between protease and anti-protease activity,
induced apoptosis of alveolar cells through deregulation
of pathways involved in oxidative stress, chronic inflam-
mation, and aberrant tissue remodeling that lead to the
destruction of the extracellular matrix (ECM) in the lung
[3,4]. Lung repair and regeneration are potential pro-
cesses to target with novel therapeutics in COPD as
abnormal tissue repair by the epithelial-mesenchymal
trophic unit can result in either fibrosis or destruction of
the ECM [5]. However, the molecular mechanisms
responsible for the pathogenesis of COPD remain poorly
understood.
Several groups have profiled gene expression in patients
with and without COPD or between patients with varying
levels of airflow obstruction in order to understand differ-
ences in gene expression related to COPD [6-11]. While
these studies have provided an initial look into the COPD
transcriptome, their results primarily relied on the use of
lung function tests to define the presence or degree of
COPD. Lung function phenotypes can neither distinguish
between obstruction in the small airways and emphysema-
tous destruction of the lung parenchyma nor provide
information about regional differences in disease severity.
Recently, McDonough et al. used micro-CT scans to
quantify the degree of emphysema in different regions of
lungs from patients with severe COPD by measuring the
mean linear intercept (Lm), a morphological measurement
of alveolar destruction [12]. In order to gain insights into
biological pathways associated with increasing emphysema
severity within a patient and explore computational strate-
gies for identifying COPD therapeutics, we obtained paired
samples from eight regions at regular intervals between
the apex and base of each explanted lung from six patients
with severe COPD (Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) stage IV) and two donor lungs.
The degree of emphysematous destruction was quantified
in one tissue sample from each region by Lm, while gene
expression was profiled in the adjacent tissue sample from
the same region.
We identified a number of genes whose expression is
associated with increasing emphysematous destruction and
found that pathways enriched among these genes were
involved in the immune response and tissue remodeling.
Using the Connectivity Map (CMap) [13], we found that
the tripeptide Gly-His-Lys (GHK) was able to reverse the
aberrant patterns of gene expression associated with
increasing emphysema severity and induce patterns of gene
expression consistent with transforming growth factor beta
(TGFb) pathway activation. Furthermore, we showed that
by treating distal lung fibroblasts from COPD patients with
GHK, we can restore normal contractile function through
re-organization of the actin cytoskeleton and up-regulation
of integrin-b1. These data further support the potential of
GHK as a therapeutic in the treatment of emphysema.
Materials and methods
Sample acquisition and processing
Single lungs (n = 6) were removed from patients treated
for severe COPD by double lung transplantation at the
University of Pennsylvania. Donor lungs (n = 2) for
which no suitable recipient was identified were released
for research use from the Gift of Life Organ Procure-
ment Organization in Philadelphia. This study was
approved by the institutional review boards and con-
forms to the Helsinki Declaration. Written informed
consent for use of these specimens and the relevant
clinical and radiological data required for this research
were obtained from each patient prior to surgery and
from the next of kin of the persons whose donated lung
was released for research. Each lung was removed from
the thorax, cooled to 1.6°C, and transported to the
laboratory where the bronchial stump was cannulated
[14]. The lung was then inflated using a compressed air
source attached to an underwater seal to slowly increase
transpulmonary pressure (PL) from 0 to 30 cmH2O.
The specimen was then held at a transpulmonary pres-
sure of 10 cmH2 Owhile frozen by liquid nitrogen vapor
(-130°C). The frozen specimen had a multidetector CT
scan followed by being cut into 2-cm thick slices in the
same plane as the CT scan. Tissue samples were col-
lected using a sharpened steel cylinder (cork bore dia-
meter of 14 mm). One sample from a cluster of four
core samples of lung obtained from each site was pro-
cessed for micro-CT [12]. A companion core from the
same cluster was used for the gene profiling and valida-
tion studies reported here. The representative nature of
these samples with respect to the entire lung was estab-
lished by comparing the densities of the sampled sites
with the frequency distribution of the densities in the
entire lung on multidetector CT as reported in McDo-
nough et al.[12].
Measurement of mean linear intercept
The severity of emphysema within each core was esti-
mated by measuring Lm. A micro-CT scan of each core
provided approximately 1,000 contiguous 16-μm thick
images. Lm was measured at 20 regularly spaced intervals
of each of the micro-CT scans using a previously
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validated grid of test lines projected onto the image and a
custom macro linked to specialized software (ImagePro
Plus; MediaCybernetics (Rockville, MD, USA). The num-
ber of intercepts between these lines and tissue was
counted. Lm was calculated as the total length of the test
lines divided by the number of cross-overs with tissue
(equal to the number of intercepts divided by 2).
Microarray sample processing
High molecular weight (mRNA-containing fraction)
RNA was isolated from tissue cores using the miRNeasy
Mini Kit (Qiagen, Valencia, CA, USA). RNA integrity
was assessed using an Agilent 2100 Bioanalyzer and
RNA purity was assessed using a NanoDrop spectro-
photometer. RNA (1 μg) was processed and hybridized
onto the Human Exon 1.0 ST array (Affymetrix Inc.,
Santa Clara, CA, USA) according to the manufacturer’s
protocol as previously described [15]. Expression Con-
sole Version 1.1 (Affymetrix Inc.) was used to generate
transcript-level gene expression estimates for the ‘core’
exon probesets via the robust multichip average (RMA)
algorithm. Gene symbols of transcript IDs were
retrieved using DAVID [16]. These gene expression data
are available through the Gene Expression Omnibus
(GEO) under the accession GSE27597.
Microarray data analysis
Two linear mixed-effects models were used to identify
gene expression profiles associated with the degree of
regional emphysema severity as measured by Lm:
1. Geneij = β0 + βSlice × Sliceij + αj + εij
2. Geneij = β0 + βSlice × Sliceij + βLm × Lmij + αj + εij
i = 1, 2, ..., 8; j = 1, 2, ..., 8
εij ∼ N(0, σ 2)αj ∼ N(0, σ 2aj)
Geneij is the log2 expression value for sample i in patient
j for a single gene. Slice is a fixed effect controlling for the
position within the lung from which the sample core was
obtained. The random term εij represents the random
error, which was assumed to be normally distributed, aj
represents the random effect for patient, and b0 represents
the intercept. Model 2 contains an additional fixed effect
term for emphysema severity measured by the natural log
of Lm. A gene’s expression profile was considered asso-
ciated with Lm if model 2 fit better than model 1 as deter-
mined by a significant P-value from a likelihood ratio test
between the two models after applying a false discovery
rate (FDR) correction. In the immunohistochemistry
experiments, these linear models were also used to exam-
ine the relationship between Lm and the volume fraction
of tissue with positive staining by substituting volume frac-
tion (Vv) for gene expression as a dependent variable. All
statistical analyses were conducted using R statistical
software v2.9.2 and the nlme package in Bioconductor
v2.4 [17].
Functional enrichment analysis
Functional enrichment analysis was performed using
DAVID 2008 or Gene Set Enrichment Analysis (GSEA)
v2.0.7 [16,18]. For DAVID, functional enrichment was
examined among Gene Ontology categories, and KEGG
and BIOCARTA pathways. All genes in the species Homo
sapiens were used as a reference set. For GSEA, genes
were ranked by the t-statistic of the bLm coefficient in the
linear mixed-effects model and then analyzed for the
enrichment of canonical pathways and Gene Ontology
term gene sets obtained from MSigDB v2.5.
Connecting to other gene-expression datasets
Using GSEA, sets of genes reported to change with
COPD-related phenotypes or with TGFb treatment in
other gene-expression studies were examined in a ranked
list of genes ordered from most induced in severe emphy-
sema to most repressed in severe emphysema by the
t-statistic of the bLm coefficient in the linear mixed-
effects model. Conversely, sets of genes we identified as
significantly positively or negatively associated with Lm
were examined within gene lists ranked by the degree of
differential expression as determined by re-analyzing pre-
viously published COPD-or TGFb-related microarray
studies. See Additional file 1 for a description of the data
normalization procedures and statistical analyses used to
generate gene sets and/or ranked gene lists for each of
the previously published gene-expression datasets.
Connectivity Map
In order to find compounds that reverse gene-expression
patterns associated with emphysema severity, we gener-
ated separate signatures for each COPD or TGFb gene-
expression dataset examined in this study. Signatures were
generated by identifying the 50 genes most up-regulated
and the 50 genes most down-regulated with respect to a
COPD or TGFb-related phenotype. Each signature was
queried against the CMap using the algorithm described
by Lamb et al. [13]. See Additional file 1 for a description
of the statistical analysis used to generate each query sig-
nature for each phenotype within each dataset. The list of
all CMap query signatures used in this analysis include: 1)
genes that change in expression as a function of regional
emphysema severity in this study; genes that change in
expression with 2) forced expiratory volume in 1 second
(FEV1), 3) FEV1/forced vital capacity (FVC), or 4) between
cases versus controls in Bhattacharya et al. [7]; genes that
change in expression between 5) controls versus emphy-
sema patients or between 6) controls versus a1-antitrypsin
disease in Golpon et al. [6]; genes that change in expres-
sion with 7) FEV1 or 8) diffusing capacity of carbon
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monoxide (DLCO) in Spira et al.[9]; genes that change in
expression with 9) FEV1, 10) FEV1/FVC, 11) DLCO, 12)
non-smokers versus GOLD2, or 13) non-smokers versus
GOLD3 in Wang et al.[10]; and genes that change in
expression with TGFb treatment from 14) Qin et al.[19],
15) Classen et al.[20], 16) Renzoni et al.[21], 17) Koinuma
et al.[22], and 18) Malizia et al.[23]. For comparison of the
CMap data to our in vitro studies of the effects of GHK in
primary lung fibroblasts, raw data for GHK-treated and
control samples were downloaded from the CMap website
and normalized using MAS5.0 with the Affymetrix CDF.
Genes were ranked by a paired t-test between treatment
and controls of different batches and compared to gene
sets of GHK and TGFb treatment using GSEA.
Isolation and culture of lung fibroblasts
Lung tissue of former smokers (defined as quitting smok-
ing for at least one year before surgery) with normal lung
function or GOLD stage IV COPD was obtained from
patients undergoing surgery for resection for pulmonary
carcinoma or lung transplantation. Fibroblast cultures
were established from parenchymal lung tissue by an
explant technique as previously described [24]. Isolated
cells were characterized as fibroblasts by morphological
appearance and expression pattern of specific proteins as
described previously [24,25]. Fibroblast cultures were
stored into liquid nitrogen until use.
Immunofluorescence
Fibroblast cultures at passage 3 were cultured in eight-
well chamber slides (Gibco, Burlington, ON, Canada) in
growth medium (DMEM, 10% fetal bovine serum (FBS),
penicillin, and streptavidin from Invitrogen, Burlington,
ON, Canada). After reaching 70% confluence, fibroblasts
were cultured for 24 h in 1% FBS DMEM and then incu-
bated with either TGFb1 10ng/ml (Peprotech, Dollard
des Ormeaux, Quebec, Canada), GHK 10 nM (Sigma,
Markham, Ontario, Canada) or control media (1% FBS
DMEM, penicillin, streptavidin) for a further 48 h. After
stimulations, chamber slides were fixed with 4% parafor-
maldehyde for 20 minutes, blocked in 10% goat serum in
phosphate-buffered saline (PBS) with 0.1% saponin for
1 h and then stained with integrin-b1 antibody (M-106,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) in 0.1%
saponin in PBS for 2 h at room temperature. Following
washing in PBS with 0.1% saponin and 0.1% Tween 20,
secondary antibody conjugated with goat anti-Mouse IgG
Alexa Fluor 488 and Phalloidin conjugated with Alexa
Fluor 594 were incubated for 2 h at room temperature.
Following final washes, cultures were incubated with
DAPI 1 ng/ml and then coverslipped with cytoseal.
Confocal images were acquired with a Leica AOBS SP2
laser scanning confocal microscope (Leica, Heidelberg,
Germany). The images were overlaid and the contrast
enhancements were performed on the images using
Volocity software™ (Improvisions Inc., Boston, MA,
USA) as previously described [26].
Collagen gel contraction assays
Fibroblast cultures at passage 3 were cultured in six-well
tissue culture plates (Gibco, Canada) in growth medium
(DMEM, 10% FBS, penicillin, and streptavidin from
Invitrogen, Canada). After reaching 70% confluence,
fibroblasts were cultured for 24 h in 1% FBS DMEM
and then incubated with TGFb1 10 ng/ml (Peprotec,
Canada), GHK 10 nM (Sigma, Canada) or growth media
control for a further 48 h. Prior to the end of the treat-
ment time point, a 12-well tissue culture plate was incu-
bated with 1% bovine serum albumin in DMEM for 2 h.
The medium was removed and then 500 µl of 0.4 mg/ml
type I collagen (BD Biosciences, Mississauga, ON,
Canada) was added and allowed to polymerize for 8 h at
37°C. The treated fibroblasts were then trypsinized and
seeded at 2 × 105 cells/500 µl of 1% FBS DMEM, penicil-
lin, streptavidin in duplicate on the collagen gels and cul-
tured for an additional 24 h at 37°C in 5% CO2. The gels
were imaged before and after and the extent of gel con-
traction measured using Image Pro Software.
Multi-photon and second harmonic generation
microscopy
The collagen gels were fixed with 4% paraformaldehyde
for 20 minutes and washed in PBS with 0.1% saponin
and 0.1% Tween 20 before being incubated with phalloi-
din conjugated with Alexa Fluor 594 for 1 h at room
temp. Gels were then mounted on to a glass slide using
Secure-seal™ imaging spacers (size 20 mm; Sigma) and
aqueous mounting media. The gels were then imaged
using second harmonic generation microscopy to deter-
mine fibrilar collagen as previously described [27]. For
each cell volume, Z-section images were compiled and
the three-dimensional image restoration was performed
using Volocity software (Improvisions, Inc.). A noise-




Lm was quantified using micro-CT scans in eight sam-
ples taken at regular intervals from apex to base of lungs
from six subjects that required transplantation for COPD
and two organ donors (Figure 1). Table 1 shows demo-
graphic information and clinical characteristics of the
eight subjects used in this study. As expected, samples
from subjects with COPD had a higher mean and a
greater range of Lm values between samples compared to
those from donor lungs, indicating that there are regions
of severe emphysema in COPD subjects (Table 1).
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Figure 1 Outline of study design. (a) Whole lungs were removed from patients with severe COPD and from donors, inflated with air, and
rapidly frozen in liquid nitrogen vapor. (b) The frozen specimens were cut into 2-cm slices from apex to base of the lung. (c) Adjacent tissue
cores were removed from 8 different slices of each lung (8 patients with 8 slices = 64 total regions). (d) Micro-CT was used to measure Lm at 20
evenly spaced intervals throughout one core from each region.
Table 1 Subject demographics for lung tissue samples
Patient ID Description Sex Age Pack years Smoking status Lm mean ± SD (μm) Lm range (μm)
6965 COPD M 62 50 Former 716 ± 164 494-982
6967 COPD F 61 25 Former 414 ± 82 334-585
6968 COPD F 63 38 Former 724 ± 252 357-1,013
6969 COPDa,b F 56 54 Former 1,822 ± 1270 521-4,620
6970 COPDc M 55 15 Former 1,352 ± 599 647-2,551
6971 COPD M 59 30 Former 1,097 ± 441 720-2,101
6982 Donor M 59 - Never 384 ± 47 344-473
6983 Donor M 62 24 Former 289 ± 41 231-352
Subjects with COPD had FEV1/FVC <70% and FEV1 <25% predicted.
a-cSome patients had other diseases: avon Willebrand disease; bhypertension; ca1-antitrypsin
deficiency disease.
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Subject 6967 was diagnosed with a pure airway obstruc-
tion COPD phenotype without emphysema [28]. Consistent
with this diagnosis, the distribution of Lm measurements
for this patient closely resembles the distribution of Lm
measurements from the donor lungs. Subject 6970 was
diagnosed with a1-antitrypsin deficiency. The remaining
four subjects with COPD had the centrilobular emphysema-
tous phenotype commonly observed in smokers. The distri-
bution of emphysematous destruction in tissue cores from
these COPD patients range from little to no emphysema
(Lm < 600) to very severe emphysema (Lm > 1,000) [12].
Subject 6969 had one sample excluded from subsequent
analysis because its Lm measurement was an outlier (more
than three times the interquartile range of the distribution
of Lm measurements in all cores from all lungs examined).
Pathways associated with regional emphysema severity
Using linear mixed-effect models, the expression levels of
127 genes were significantly associated with Lm and thus
associated with regional emphysema severity (Figure 2a;
FDR <0.10; see Additional file 2 for the analytic results
for all genes). Using DAVID [16] or GSEA [18], we found
that genes with functions in the B-cell receptor signaling
pathway were over-represented among the up-regulated
genes, while genes involved in cellular structure, integrin
signaling, extracellular matrix production, focal adhesion,
blood vessel morphogenesis, and the vascular endothelial
growth factor and TGFb pathways were enriched among
the down-regulated genes (FDR <0.05; see Additional
file 3 for a list of all significantly enriched pathways). The
expression of CD79A, a component of the B-cell recep-
tor, increased in expression with increasing emphysema
severity (Figure 2b), and the expression of ACVRL1 (also
known as activin-like kinase I), a receptor in the TGFb
pathway, decreased in expression with increasing emphy-
sema severity (Figure 2c). These two genes are shown as
examples of the characteristic relationship between Lm
and gene expression as observed in Figure 2a. To predict
transcription factors that might be responsible for the
observed patterns of differential expression, we inferred a
gene expression relevance network using the Context
Likelihood of Relatedness (CLR) algorithm [29]. Tran-
scription factors with the most connections to other
genes included EPAS1 (also known as HIF-2a), KLF13,
TAL1, TBX3, GATA2, and BCL11A (Additional file 4).
Fourteen genes whose expression is significantly corre-
lated with regional emphysema severity or transcription
factors that are highly connected to these genes in the
relevance network were selected for quantitative RT-PCR
validation in a subset of tissue cores from subjects with
severe emphysema (see Additional file 1 for methods).
Twelve out of the fourteen genes had a significant corre-
lation between the expression values derived from the
microarray and quantitative RT-PCR, showing that the
association of gene expression with regional emphysema
severity is reproducible across assays (Pearson correla-
tion, P < 0.05; Additional file 5).
In order to demonstrate that the 127 gene signature is
related to regional emphysema severity within individuals
and not to differences between donors and COPD patients
or to differences in levels of emphysema between COPD
patients, we repeated the same statistical analysis while only
including the five COPD patients with emphysema and
standardizing the Lm measurements within each patient
core to a mean of zero and a standard deviation of one
(Z-score). Using GSEA, the sets of up-and down-regulated
genes in the 127-gene signature identified in the previous
analysis with all eight patients and unscaled Lm measure-
ments were concordantly enriched among genes differen-
tially expressed when only the five emphysema patients
were analyzed with Z-scored Lm measurements, indicating
that this gene signature is associated with regional emphy-
sema severity (FDR <0.001, GSEA; see Additional file 6 for
the enrichment plot).
Validation of pathways up-regulated in regions of severe
emphysema
In order to investigate whether the up-regulation of com-
ponents of the B cell receptor signaling pathway is asso-
ciated with a change in the quantity of B cells in lung
tissue, we quantified the Vv of CD79A protein, a marker
for B cells, in relation to Lm by immunohistochemistry
(see Additional file 1 for methods). CD79A-positive B cells
were observed in the alveolar and small airway wall tissue
(Figure 3). Vv was quantified in alveolar tissue for all 64
samples and in small airway tissue for 43 samples that con-
tained small airways and was found to be positively corre-
lated to Lm in both the alveolar and small airway wall
tissue (P < 0.001), indicating that B cell abundance
increases as emphysema severity increases.
Validation of pathways down-regulated in regions of
severe emphysema
Several members of the TGFb pathway were among the
genes that had decreased expression as a function of regio-
nal emphysema severity. These genes included ACVRL1,
ENG, TGFBR2, and SMAD6. Other components in this
family, including BMPR2 (FDR q-value = 0.125) and
SMAD7 (FDR q-value = 0.223), also showed evidence of
modest down-regulation while SMAD1 showed evidence
of modest up-regulation (FDR q-value = 0.101). To deter-
mine whether the TGFb pathway might be affected by
emphysema pathogenesis, we used seven previously pub-
lished studies that had examined the effect of TGFb
ligands on gene expression to develop a collection of sig-
natures of TGFb pathway activation [19-23,30,31]. Genes
that exhibited significantly decreased expression with
increasing emphysema severity were enriched among
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genes induced in response to TGFb treatment in a total of
three datasets (FDR <0.05, GSEA). Similarly, the sets of
genes most induced by TGFb from each of the seven data-
sets examined were enriched among genes whose expres-
sion decreased as a function of emphysema severity (FDR
<0.05, GSEA). As an example, the enrichment of genes
associated with emphysema severity among genes chan-
ging with TGFb treatment in the dataset from Malizia
et al. [23] is shown in Figure 4a,b. See Additional file 7 for
the GSEA enrichment plots for all seven datasets.
To further validate these findings, we cultured human
lung fibroblasts with and without TGFb1 and found that
the set of genes most induced by TGFb1 were enriched
among genes that decrease in expression with increasing
regional emphysema severity (FDR <0.05, GSEA; see Addi-
tional file 8 for the GSEA enrichment plot and Additional
file 1 for the fibroblast culture methods). Immunostaining
of lung tissue from the same regions on which we
performed gene expression analysis localized SMAD2, a
down-stream signal transducer of TGFb, to the alveolar
and airway walls while members of the bone morphoge-
netic protein (BMP) pathway, including SMAD6 and
SMAD1, were primarily seen in vascular endothelial cells
(Additional file 9).
Relationship to expression profiles in other COPD studies
In order to show that the gene expression signature of
regional emphysema severity is present in larger cohorts
of patients with earlier stages of disease, we used GSEA to
examine the relationship between genes associated with
regional emphysema severity in this dataset and genes
associated with COPD phenotypes in other cross-sectional
studies [6-11]. The genes that decreased in expression
with increasing emphysema severity were significantly
enriched among genes down-regulated as a function of
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Figure 2 Gene expression signature of regional emphysema severity. (a) Supervised heatmap of genes whose expression is associated with
Lm (FDR <0.10). Samples are organized from low to high Lm. Each row corresponds to a gene and each column corresponds to a sample.
Green represents lower relative expression and red represents higher relative expression. (b,c) Expression of CD79A (b) and ACVRL1 (c) are
plotted against the natural log of Lm with the color of each point indicating the subject from which the sample was derived.
Campbell et al. Genome Medicine 2012, 4:67
http://genomemedicine.com/content/4/8/67
Page 7 of 16
published datasets that we examined (FDR <0.05, GSEA;
Additional file 10). In addition, genes that increased in
expression with increasing emphysema severity were
enriched amongst genes up-regulated as a function of
COPD-related phenotypes in three of the five datasets
(FDR <0.05, GSEA). As an example, the enrichment of
genes associated with regional emphysema severity among
genes differentially expressed with the presence of emphy-
sema in the dataset from Golpon et al.[6] is shown in
Figure 4c,d. Conversely, sets of genes reported to be differ-
entially expressed with COPD in four of the six other
cross-sectional studies were enriched among the genes
changing in expression with increasing regional emphy-
sema severity (FDR <0.05, GSEA; Additional file 10).
Examples of genes validated by quantitative RT-PCR in
this study and concordantly differentially expressed in
other studies are shown in Additional file 11. Many of
these datasets, such as Bhattacharya et al.[7] and Wang
et al.[10], contained larger numbers of patients with a vari-
ety of stages of disease (for example, GOLD stage 0
through GOLD stage IV). The enrichment of genes asso-
ciated with regional emphysema severity with COPD-
related phenotypes in these other datasets suggests that
the biological processes associated with increasing emphy-
sema severity within a patient with severe COPD also vary
in individuals with earlier stages of disease.
Prediction of novel therapeutics for emphysema
In order to identify compounds that might reverse the
gene-expression pattern associated with progression of
emphysema, we utilized the CMap [13], a compendium of
microarray experiments that measure the effect of thera-
peutic compounds on gene expression in cancer cell lines.
Signatures of genes that 1) change in expression with
regional emphysema severity in this dataset, 2) change in
expression with lung function measures in other datasets
[6,7,9,10], or 3) change in expression with TGFb treatment
in other datasets [19-23] were each used as separate
queries into the CMap data. We found that gene expres-
sion changes resulting from treatment with the tripeptide
GHK, a compound thought to accelerate wound healing
[32,33], were negatively correlated with expression pat-
terns associated with increasing regional emphysema
severity (P = 0.006) and the COPD-related expression pat-
terns observed in Bhattacharya et al.[7] and Golpon et al.










Figure 3 Validation of differential expression for CD79A by immunohistochemistry. Representative images of CD79A-positive cells (arrows)
in the alveolar tissue and the small airway walls. Positive staining appears red. Scale = 200 µm; inset = 10 µm.
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GHK are similar to the effects of TGFb treatment
observed by Malizia et al.[23] (P = 0.004).
As the CMap examined the effect of GHK in cancer cell
lines, we next sought to verify the effect of GHK treatment
in a cell type more relevant to emphysema pathogenesis.
We utilized human lung fibroblasts because fibroblasts are
the major interstitial cell within the alveolar unit that can
synthesize and remodel the ECM and previous studies
have demonstrated that GHK can induce ECM production
in dermal fibroblasts [32-34]. Human lung fibroblast cul-
tures were treated with two concentrations of GHK or
with TGFb1 (see Additional file 1 for methods). Gene
expression profiling of these cells demonstrated that the
200 genes most induced by GHK at 1 μM in cancer cell
lines in the CMap dataset were enriched among genes that
increased after treatment with GHK at 0.1 nM in
fibroblast cultures (FDR <0.05, GSEA). Furthermore,
genes whose expression is decreased with increasing
emphysema severity are enriched among genes induced by
GHK at 10 nM (FDR < 0.05, GSEA; Figure 5a,b). Genes
whose expression is altered by GHK treatment at either
concentration are also enriched among genes that change
with TGFb1 treatment (FDR <0.05, GSEA; Figure 5c,d).
See Additional file 8 for the GSEA enrichment plots show-
ing the relationship between GHK, TGFb, and emphysema
severity signatures.
Reversal of COPD-related phenotypes in fibroblasts
by GHK
Genes induced in human lung fibroblasts after treat-
ment with GHK were enriched in actin cytoskeleton
organization and focal adhesion pathways (FDR < 0.05,
Down-regulated with regional emphysema severity































Figure 4 Relation between gene expression changes associated with regional emphysema severity (Lm) and other gene-expression
studies by GSEA. (a) Relation between gene expression changes associated with regional emphysema severity and those induced by TGFb
treatment of A549 cells from Malizia et al.[23]. The color bar represents the fold change between the cell lines treated with and without
TGFb1for 11,910 genes in Malizia et al.[23]. Red indicates a more positive fold change and green indicates a more negative fold change (induced
or repressed with TGFb, respectively). The vertical lines represent the position of genes associated with regional emphysema severity in the
ranked gene list. The height of the vertical lines corresponds to the magnitude of the running enrichment score from GSEA. Blue vertical lines
indicate that the gene is part of the ‘core’ enrichment (that is, all the genes from the absolute maximum enrichment score to the end of the
ranking). (b) Supervised heatmaps of relative gene expression levels for the core enrichment genes in both the regional emphysema and Malizia
et al. datasets (11 genes down-regulated with emphysema severity but up-regulated with TGFb). Each gene is represented in the same row
across heatmaps. (c) Genes changing in expression with increasing regional emphysema severity were enriched in the cross-sectional study of
COPD-related gene expression from Golpon et al.[6]. The color bar represents the t-statistic from a t-test between five emphysema patients and
five non-smokers for 5,209 genes in Golpon et al.[6]. Blue and orange vertical lines indicate that the gene is part of the core enrichment.
(d) Supervised heatmaps of relative gene expression levels for the core enrichment genes in both the regional emphysema and Golpon datasets
(8 genes concordantly up-regulated; 19 genes concordantly down-regulated).
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DAVID). These included integrins involved in collagen
attachment, such as ITGB1. ITGB1 gene expression was
also down-regulated with increasing emphysema severity
in lung tissue (P = 0.008). Resolution of damaged tissue
requires mesenchymal cells to attach to collagen fibers
through integrin-dependent mechanisms and generate
mechanical tension via the actin cytoskeleton to promote
tissue contraction and wound size reduction. Using distal
lung fibroblasts isolated from former smokers with and
without COPD, we found that GHK (10 nM), like TGFb1
(10 ng/ml), induced alterations in integin-b1 localization
(green staining in Figure 6a) and reorganized actin to
form contractile filaments (red staining in Figure 6a). We
further demonstrated using a three-dimensional collagen
gel contraction bioassay that distal lung fibroblasts
derived from former smokers with COPD (n = 5) were
unable to fully contract collagen I gels compared to fibro-
blasts obtained from former smokers without COPD (n =
5, P < 0.05; Figure 6b,c; see Additional file 12 for subject
demographics), similar to what has been previously
described [35]. However, fibroblasts derived from COPD
patients first treated for 48 h with either TGFb1 or GHK
were able to induce full collagen I gel contraction com-
parable to that observed in fibroblasts from former
smokers without COPD (P < 0.01, Figure 6b,c). Using the
second harmonic generation properties of fibrilar col-
lagen and multi-photon microscopy, we confirmed that
fibroblasts from former smokers with COPD were unable
to efficiently remodel collagen into fibrils (Figure 6d).
Importantly, following 48 h of treatment with TGFb1 or
GHK on lung fibroblasts from former smokers with
COPD, we were able to restore this intrinsic defect,
which we propose is through organization of the actin
cytoskeleton to a contractile phenotype as demonstrated
by the confocal images displayed in Figure 6a.
Discussion
The goal of this study was to identify gene expression
changes associated with regional emphysema severity in
order to elucidate biological processes underlying the pro-
gression of emphysema and to identify potential COPD
therapeutics. By measuring gene expression from regions
of varying emphysema severity within the same lung and
by using a morphologic measurement of airspace size
(Lm), which reflects the degree of alveolar destruction, we
were able to identify gene expression changes associated
specifically with the emphysematous component of
COPD.

























Figure 5 Effect of GHK treatment on expression in human lung fibroblasts. (a) Genes decreasing in expression with increasing regional
emphysema severity were enriched among genes that are induced by GHK at 10 nM. (b) Supervised heatmaps of relative gene expression
levels for the core enrichment genes in both datasets (18 genes down-regulated with Lm but up-regulated with GHK). Each gene is represented
in the same row across heatmaps. (c) Genes differentially expressed with treatment of GHK at 0.1 nM were concordantly enriched among genes
that change with treatment of TGFb1. (d) Heatmap of relative gene expression levels for the core enrichment genes (118 genes up-regulated
and 124 down-regulated with both GHK and TGFb1).
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Figure 6 Effect of GHK treatment on collagen contraction by fibroblasts from former smokers with COPD. (a) Representative
immunofluorescent images of distal lung fibroblasts from former smokers with and without COPD treated with GHK (10 nM), TGFb1 (10 ng/ml),
or media control for 48 h and stained with phalloidin to localize the actin cytoskeleton (red), integrin-b1antibody (green) and DAPI to localize
nuclei (blue). (b) Representative images of collagen I gel bioassays at 24 h after being seeded with distal lung fibroblasts from former smokers
with and without COPD previously treated with GHK, TGFb1, or media control for 48 h. (c) The percentage of collagen I contraction was
significantly decreased in fibroblasts derived from former smokers with COPD compared to former smokers without COPD (P < 0.05) but was
significantly increased with addition of TGFb1 or GHK (P < 0.01). (d) Representative enface Z-stack slices of three-dimensional reconstructed
collagen I gel bioassays demonstrating actin in fibroblasts (green, phalloidin) and second harmonic signal originating from collagen fibrils
(purple, 414 nM). Fibroblasts from former smokers with COPD were unable to efficiently remodel collagen into fibrils. However, this intrinsic
defect was restored with treatment of TGFb1 or GHK.
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Interestingly, there was significant enrichment between
genes differentially expressed in COPD or associated
with worsening lung function in other datasets and those
we found to be associated with regional emphysema
severity. Importantly, this similarity supports the notion
that regional differences in emphysema severity reflect
the processes that occur with general COPD pathogen-
esis and progression and are not only present in patients
with end-stage disease. Overall, these observations sug-
gest a similarity in the gene expression alterations that
accompany airflow obstruction, gas exchange abnormal-
ities, and alveolar destruction measured by Lm.
A common characteristic in the pathology of COPD is
progressive lymphocyte infiltration of the small airways
and alveolar walls [36]. In addition, the formation of ter-
tiary lymphoid organs within this infiltration suggests the
presence of an adaptive immune response to persistent
foreign or autoimmune antigens [37,38]. The present
study extends these observations by showing that the
expression patterns of several components of the B-cell
receptor signaling pathway have increased expression in
regions of severe emphysema. Iga (CD79A) and Igb
(CD79B) are proteins that associate with the B-cell recep-
tor and transmit its signal upon stimulation. Immunohis-
tochemistry showed a significant relationship between the
volume fraction of the airway wall and alveolar tissue posi-
tively stained for CD79A and an increase in Lm. This rela-
tionship supports an increased number of B cells in both
airway wall and alveolar tissues and is consistent with the
induction of CD79A during tissue destruction associated
with the increase in Lm.
The TGFb signaling pathway is involved in a variety of
cellular processes, including immune response, extracel-
lular matrix remodeling, angiogenesis, and cell differen-
tiation. This pathway has also been implicated in a
variety of diseases such as cancer and fibrosis [39]. It has
been hypothesized that the TGFb pathway could play a
role in COPD pathogenesis, but its role is not completely
understood [40]. Togo et al.[35] found that fibroblasts
isolated from COPD patients exhibited reduced chemo-
taxis, reduced nuclear to cytoplasmic ratios of phos-
phorylated SMAD3, and decreased a-smooth muscle
actin production compared to controls when treated with
TGFb. Decreased mRNA expression or protein levels for
TGFb1, TGFBR1 [41], SMAD3 [42], SMAD6 [43], and
SMAD7 [41,43] have been reported in more advanced
stages of COPD or fibroblasts from COPD patients. In
both alveolar and bronchiolar epithelium of emphysema-
tous lungs, a decrease in phosphorylated SMAD2 has
been shown by immunohistochemistry [44]. In normal
human lung parenchyma, repair processes in response to
mechanical injury are associated with increased TGFb
signaling, while a decrease in expression has been
observed for TGFb-related genes with worsening lung
function in patients with COPD [25,45]. Furthermore,
association studies have identified both promoter and
coding region polymorphisms in the TGFb1 gene that
associate with increased risk for COPD [46-48]. In the
present study, we identified several components of the
TGFb and BMP pathways that have decreasing expres-
sion with increasing emphysema severity. In the BMP
pathway, ACVRL1 and ENG are receptors involved in
the phosphorylation of SMAD1 and are expressed in the
mature lung vasculature. The changing expression of
SMAD6 and SMAD1, their localization predominantly to
vascular endothelial cells, and the roles of ACVRL1 and
ENG in angiogenesis support the hypothesis of aberrant
tissue remodeling in the lung vasculature during emphy-
sema pathogenesis. In the TGFb pathway, TGFBR2 is a
receptor involved in the phosphorylation of SMAD2/3
and is important for many tissue remodeling processes,
including wound repair. Moreover, genes found to be
induced by TGFb in diverse studies were down-regulated
in regions of severe emphysema. The localization of
SMAD2 to alveolar and airway tissue and the decreased
TGFb pathway activity seen with increasing emphysema
severity support the hypothesis that a decrease in TGFb
pathway activity also contributes to emphysema
pathogenesis.
As COPD remains a major public health concern due to
lack of effective therapeutic strategies, we sought to use
computational methods to identify compounds that might
modulate molecular processes associated with emphysema
pathogenesis. The CMap is a large compendium of micro-
array experiments that measures the effect of over 1,000
compounds on gene expression in several cell lines [13].
By querying a gene expression signature of disease patho-
genesis against the CMap dataset, one can find com-
pounds that elicit a pattern of gene expression that is the
opposite to the disease-related gene expression profile.
This can lead to the hypothesis that such compounds,
since they reverse the disease-related gene expression pat-
tern, are potential therapeutics for that disease. This
approach has been recently successful in the therapeutic
repositioning of the antiulcer drug cimetidine to lung ade-
nocarcinoma and the anticonvulsant drug topiramate to
inflammatory bowel disease [49,50]. In these studies, sig-
natures for each disease were derived using several pub-
licly available gene-expression datasets and queried in the
CMap. Candidate compounds or drugs that could signifi-
cantly reverse the disease-related signatures of gene
expression were further validated in vitro, showing that
this computational method is a viable approach for identi-
fying novel therapeutics.
Using the CMap dataset, we identified a relationship
between the gene expression changes induced by the tri-
peptide GHK and those that are repressed with increasing
emphysema severity. Intriguingly, we further found that
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GHK-treatment induced a pattern of gene expression
similar to that resulting from TGFb pathway activation.
We replicated both of these findings in human lung fibro-
blasts, which are the major interstitial cells that maintain
tissue structural integrity by sculpting the connective tis-
sue. GHK-Cu is a natural tripeptide that, in human
plasma, can be found at a concentration of 200 ng/ml at
the age of 20 years but drops to around 80 ng/ml by the
age of 60 years [34]. Characterization GHK-Cu in skin
wound repair models suggests that it induces wound con-
traction, cell proliferation, angiogenesis, and increased
expression of antioxidant enzymes and integrins [34,51].
Direct evidence for the ability of GHK-Cu to promote
wound healing comes from experimental rat models
where GHK treatment causes an acceleration of healing
and a concentration-dependent increase of connective tis-
sue and other ECM components [32,33]. These effects are
consistent with the gene expression alterations induced by
GHK and TGFb treatment. Moreover, we confirmed these
similarities by demonstrating that GHK and TGFb
induced significantly higher expression and re-organiza-
tion of actin and integrin-b1 in distal lung fibroblasts.
We further assessed the ability of GHK and TGFb to
induce tissue contraction. As in previous studies [35],
we demonstrated that distal lung fibroblasts derived
from COPD patients have intrinsic defects in collagen I
contraction compared to fibroblasts derived from former
smokers without COPD. When fibroblasts from COPD
lungs were treated with GHK or TGFbcontraction and
remodeling of collagen gels was induced to levels com-
parable to fibroblasts from former smokers without
COPD. We further demonstrated that the collagen con-
traction induced in COPD fibroblasts by GHK involves
the organization of collagen I gels into collagen fibrils
using multi-photon microscopy. Taken together, these
data further support the hypothesis in which a wound-
healing-like process is diminished as a function of
emphysema progression and further suggest that this
process is related to the TGFb pathway.
While the number of subjects in this study for genomic
analysis was small, the analysis of eight specimens per
lung representing different degrees of emphysema from
each individual allowed us to detect gene expression
changes specifically associated with regional emphysema
severity. We further demonstrated that these genes are
concordantly differentially expressed in previous cross-
sectional studies involving larger numbers of individuals
with varying degrees of airflow limitation. These results
validate the gene expression differences associated with
regional emphysema severity in independent cohorts
from different clinical settings and support the hypoth-
esis that the genes whose expression is associated with
regional emphysema severity reflect the activity of true
disease-associated processes. As demonstrated by our
micro-CT data, COPD is a heterogeneous disease within
the lung [12]. Further studies will be required to assess
whether COPD-associated differences in ECM remodel-
ing by distal fibroblasts in vitro is associated with the
regional disease severity in the tissue from which the
fibroblasts are derived.
Conclusions
This study has provided insights into molecular pro-
cesses associated with emphysematous destruction of
the lung and revealed mechanisms that contribute to
the pathogenesis of COPD. Whole genome gene-expres-
sion analysis supports the role of the immune response
in regional emphysema and elucidates additional path-
ways involved in the process of emphysematous destruc-
tion. The suggestion that progressive emphysematous
destruction is associated with down-regulation of genes
involved in or downstream of tissue remodeling and
wound repair pathways supports a role for defects in
ECM homeostasis and angiogenesis in the emphysema-
tous destruction that occurs with chronic inflammation
in COPD. We propose that these processes could be
linked through decreased TGFb pathway activation.
These data are supported by our identification of GHK
as a compound with the potential to mimic TGFb path-
way activity and induce collagen contraction, an impor-
tant functional component of wound repair.
Additional material
Additional file 1: Supplementary methods.
Additional file 2: Statistical results for gene expression analysis.
Additional file 3: Functional categories enriched among genes
associated with regional emphysema severity.
Additional file 4: Gene expression relevance network. Dark blue
circles are genes that have expression significantly correlated with Lm;
light blue circles are all other genes. Edges are indicated by green
(positive correlation) or red (negative correlation) lines.
Additional file 5: RT-PCR validation of 14 genes associated with
regional emphysema severity.
Additional file 6: Confirmation of gene expression changes
associated with regional emphysema severity (Lm) within individuals
with emphysema using GSEA. Genes associated with unscaled Lm
measurements identified using all eight patients in the analysis are
concordantly enriched among genes associated with scaled Lm
measurements (Z-scored within each patient) using only the five
emphysema patients (FDR <0.001). These results demonstrate that the 127
gene signature is related to regional emphysema severity within individuals
and not to differences between donors and COPD patients or to differences
in levels of emphysema between COPD patients. Orange and blue color
bars represent the t-statistics from correlations of gene expression with Lm.
The vertical black lines represent the position of genes in the gene set
among the ranked gene list. The length of the black lines corresponds to
the magnitude of the running enrichment score from GSEA.
Additional file 7: Relation between gene expression changes
associated with regional emphysema severity (Lm) and studies of
TGFb-related gene expression using GSEA. Genes associated with Lm
are enriched among the genes that are differentially expressed in response
to TGFb treatment in datasets from (a) Classen et al.[20], (b) Koinuma et al.
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[22], and (c) Malizia et al.[23]. (d) Genes most induced by TGFb in seven
studies [19-23,30,31] are enriched among the genes that are associated with
Lm. Orange and blue color bars represent the t-statistics from correlations
of gene expression with a continuous variable. Red and green color bars
represent the fold change between samples treated with and without
TGFb. The vertical black lines represent the position of genes in the gene
set among the ranked gene list. The length of the black lines corresponds
to the magnitude of the running enrichment score from GSEA. Enrichments
with an FDR q-value <0.05 were considered significant.
Additional file 8: Relation between gene expression changes
associated with regional emphysema severity (Lm) and gene
expression changes that occur with treatment of GHK or TGFb in
fibroblast cell lines using GSEA. (a) Genes increasing in expression in
response to treatment with GHK or TGFb are enriched among genes that
decrease with increasing emphysema severity. (b) Genes differentially
expressed with TGFb treatment or in response to GHK in the
Connectivity Map are enriched among genes that change in expression
with GHK (0.1 nM) in fibroblast cell lines. (c) Genes that are differentially
expressed with TGFb treatment or that are down-regulated with
increasing emphysema severity are enriched among genes that change
in expression with GHK (10 nM) in fibroblast cell lines. (d) Genes that are
differentially expressed in response to GHK are concordantly enriched
among genes that change in expression with TGFb treatment in
fibroblast cell lines. Orange and blue color bars represent the t-statistics
from correlations of gene expression with a continuous variable. Red and
green color bars represent the t-statistic between treated and untreated
samples. The vertical black lines represent the position of genes among
the ranked gene list. The length of the black lines corresponds to the
magnitude of the running enrichment score from GSEA. Enrichments
with an FDR q-value <0.05 were considered significant.
Additional file 9: Localization of members of the TGFb superfamily
using immunohistochemistry. Representative images of positive
SMAD2 staining (arrows) in the (a) alveolar and (b) small airway wall
tissue. (c) Representative image of positive SMAD6 staining in vascular
endothelial cells (arrows) and macrophages (arrowheads). (d)
Representative image of weak SMAD1 staining in vascular endothelial
cells (arrows). Representative images are shown for control IgG staining
in the (e) alveolar wall tissue, (f) airway wall tissue, and (g) blood vessels.
Scale bar = 200 µm.
Additional file 10: Relation between gene expression changes
associated with regional emphysema severity (Lm) and cross-sectional
studies of COPD-related gene expression using GSEA. Genes associated
with Lm are enriched among the genes found to associated with the
presence of COPD or degree of airflow obstruction in datasets from
(a) Golpon et al.[6], (b) Spira et al.[9], (c) Wang et al.[10], and (d) Bhattacharya
et al.[7]. (e) Genes previously found to be associated with COPD-related
clinical variables [6,8-10] are enriched among the genes associated with Lm.
Orange and blue color bars represent the t-statistics from correlations of gene
expression with a continuous variable. Red and green color bars represent the
t-statistic from a t-test between cases and controls. The vertical black lines
represent the position of genes in the gene set among the ranked gene list.
The length of the black lines corresponds to the magnitude of the running
enrichment score from GSEA. Enrichments with an FDR q-value <0.05 were
considered significant.
Additional file 11: Examples of genes associated with Lm and
validated by quantitative RT-PCR that were also differentially
expressed in other COPD-related gene-expression datasets. Genes
such as ACVRL1, SMAD6, CCR7, and CXCL13 were associated with increasing
regional emphysema severity and concordantly differentially expressed in
other datasets such as Golpon et al.[6] and/or Wang et al.[10].
Additional file 12: Subject demographics for lung fibroblast cultures.
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